Quince Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Dirk Thye
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 20.1% |
| CEO tenure | 3yrs |
| CEO ownership | 2.0% |
| Management average tenure | 2.2yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
Aug 20Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation
Nov 21
Cortexyme to change name and ticker symbol next month
Jul 27Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
Mar 01Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Dec 15We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
Dec 15Cortexyme: A Challenging Path Forward
Nov 17Cortexyme: Positive Lessons To Be Learned From Disappointing Results
Nov 01Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Oct 11Cortexyme: Alzheimer's Readout In November A Binary Event
Sep 12We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth
Aug 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$3m | US$550k | -US$57m |
| Sep 30 2024 | n/a | n/a | -US$53m |
| Jun 30 2024 | n/a | n/a | -US$53m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$1m | US$550k | -US$31m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$5m | US$317k | -US$52m |
Compensation vs Market: Dirk's total compensation ($USD2.73M) is above average for companies of similar size in the US market ($USD664.94K).
Compensation vs Earnings: Dirk's compensation has increased whilst the company is unprofitable.
CEO
Dirk Thye (54 yo)
3yrs
Tenure
US$2,732,125
Compensation
Dr. Dirk Thye, M.D., served as Chief Executive Officer, President and Director at Novosteo Inc. He has been Director at Kainomyx, Inc. Dr. Thye serves as Chief Medical Officer of Quince Therapeutics, Inc....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Medical Officer & Director | 3yrs | US$2.73m | 1.95% $ 903.2k | |
| President | 1.7yrs | US$893.05k | 0.28% $ 128.6k | |
| Chief Business Officer | 2.2yrs | US$1.37m | 0.69% $ 319.9k | |
| Chief Technology Officer | 1.6yrs | no data | no data | |
| Chief Scientific Officer | 1.6yrs | no data | 0.034% $ 15.8k | |
| Vice President of Corporate Communications & Investor Relations | 4.2yrs | no data | no data | |
| Vice President of Human Resources | 5.3yrs | no data | no data | |
| Head of Discovery | 3yrs | no data | no data | |
| Head of Regulatory Affairs | 1.8yrs | no data | no data |
2.2yrs
Average Tenure
54yo
Average Age
Experienced Management: QNCX's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Medical Officer & Director | 3yrs | US$2.73m | 1.95% $ 903.2k | |
| Lead Independent Director | 6.3yrs | US$86.14k | 0.0065% $ 3.0k | |
| Member of Scientific Advisory Board | no data | US$44.84k | no data | |
| Member of Clinical Advisory Board | 5.9yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Chairman of the board | 9.4yrs | US$93.64k | 9.96% $ 4.6m | |
| Independent Director | 6.2yrs | US$75.14k | 0% $ 0 | |
| Independent Director | 9.4yrs | US$69.64k | 0.018% $ 8.4k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 1.3yrs | no data | no data |
6.2yrs
Average Tenure
58.5yo
Average Age
Experienced Board: QNCX's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 23:16 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quince Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Kumaraguru Raja | Brookline Capital Markets |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |